PhD Scientific Days 2023

Pathology - Posters D

Beyond the Petri Dish: Advancing Drug Development with 3D Bioprinted Tumor Models

Előadó neve

Dr. Moldvai, Dorottya

Neptun code

JQCZNN

Előadó munkahelye

Department of Pathology and Experimental Cancer Research

Előadó telefonszáma

+36203291961

Előadó e-mail címe

moldvai.dorottya@gmail.com

Az előadás címe

Beyond the Petri Dish: Advancing Drug Development with 3D Bioprinted Tumor Models

Szerző(k) neve és munkahelye

1 Dorottya Moldvai Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest
2 Dániel Sztankovics Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest
3 Titanilla Dankó Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest
4 Gábor Petővári Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest
5 Ildikó Krencz Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest
6 Risa Miyaura Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest
7 Rebeka Gelencsér Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest
8 Anna Sebestyén Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest

Bemutatás módja

Poszter

Szekció

Pathology - Posters D

Language of the presentation

Hungarian

Preferred session

Pathology and Oncology

Összefoglaló szövege

Introduction
Both FDA’s and EMA’s aim to substitute animal testing has created an urgent need for alternative testing methods. The development of in vitro 3D models has been accelerated as these tools could ensure improved accuracy and reproducibility to meet the demand for creating more effective testing methods.

Aims
Although 3D bioprinted tissue-mimetic structures (TMS) have similarities to traditional in vitro 2D cell cultures, the differences require validation of the analytical methods used in 2D cell cultures. The aim of our work was to determine the functionality of cell proliferation tests in 3D bioprinted structures and to prepare these structures for further analytical studies.

Methods
Using a 3D bioprinter (GeSiM Bioscaffolder3.2), we established and optimized the printing process (bioink, settings) and the further maintenance conditions for various tumor cell lines (breast, glioma, RCC etc). Cell proliferation assays (Alamar blue, sulphorhodamine B, and calcein-assay) were validated using an m-cherry labeled fluorescent cell line (T47D). The printed TMSs were used to develop sample preparation protocols suitable for performing analytical methods (IHC, Wes Simple, proteomics). Differences in cellular metabolism were investigated by WES Simple (p-S6, p-mTOR, Rictor, CPT1A, FASN).

Results
The printed TMSs could be maintained for three weeks and exhibited persistent cell growth during this period (validated with various proliferation assays and histologic analysis of prepared formalin-fixed and paraffin-embedded tissue sections). To analyze the metabolic features of the TMSs, we compared the 3D bioprinted cultures to traditional 2D cell cultures. Our results demonstrated that the growth conditions have a significant impact on the cellular metabolic enzyme expression profile.

Conclusion
Our results underlie the need for the development of novel drug testing methods using 3D bioprinted tissues instead of traditional in vitro models. This approach could potentially accelerate the drug development process and reduce the need for animal testing.

Supported by: NKFI-FK-128404, EFOP-3.6.3-VEKOP-16-2017-00009, TKP2021-EGA, ÚNKP-22-4-II-SE-9

University and Doctoral School

Semmelweis University, Doctoral School of Pathological Sciences

Supervisor

Dr. Sebestyén Anna DSc

Publication of my abstract

I do not give consent to the publication of my abstract on the website of the congress.

Kind

Szabad

Status

elfogadva

Accepted presentation method

poszter

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

6117

Start

11:12

End

11:17

Authors (legacy)

1 Dorottya Moldvai Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest
2 Dániel Sztankovics Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest
3 Titanilla Dankó Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest
4 Gábor Petővári Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest
5 Ildikó Krencz Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest
6 Risa Miyaura Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest
7 Rebeka Gelencsér Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest
8 Anna Sebestyén Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest